



CURRICULUM VITAE

Najibeh Shekari

Assistant Professor, Department of Immunology, Tabriz University of Medical Sciences

H index

Google Scholar: 14

Scopus: 12

Scopus author ID:

57201410075

ORCID ID:

<https://orcid.org/0000-0003-3139-1035>

Google Scholar:

<https://scholar.google.com/citations?user=9bICm5YAAAAJ&hl=en>

ResearchGate profile:

<https://www.researchgate.net/profile/Najibeh-Shekari>

WOS Profile:

<https://www.webofscience.com/wos/author/record/ABI-4798-2020>

Sex: Female

Date of Birth: 14th. Feb. 1991

Nationality: Iranian

Marital Status: Single

CONTACT

Email:

shekarin@tbzmed.ac.ir

Najibe.shekari@gmail.com

Phone/Fax:

+98 41 33364665

Address:

Department of Immunology,
Faculty of Medicine, Tabriz
University of Medical Sciences,
Tabriz, Iran

Educational Background:

1. B.Sc. (2009-2013): Medical Laboratory Sciences; Tabriz University of Medical Sciences, Faculty of Paramedicine, Tabriz, Iran
2. M.Sc. (2014-2018): Immunology; Tabriz University of Medical Sciences, School of Medicine, Tabriz, Iran
3. Ph.D. (2019- 2024): Immunology; Shahid Beheshti University of Medical Sciences, School of Medicine, Tehran, Iran

Professional Experiences:

1. Laboratory Expert, Imam Hossein Hospital, Hashtroud (2014-2016)
2. Laboratory Expert & Office Manager of the Immunology Department, Faculty of Medicine, Tabriz University of Medical Sciences (2016-2017)
3. Laboratory Expert, Azarabadeghan Medical Laboratory (2018)

Educational Information:

- ✓ M.Sc. Graduation score (18.19 out of 20)
- ✓ M.Sc. Thesis score (20 out of 20)
- ✓ M.Sc. Thesis title: Effect of Docetaxel anti-cancer drug on the expression level of let-7a and miR-21 in gastric cancer cell lines
- ✓ Ranking the 6th in PhD entrance exam of Medical Immunology (2019)
- ✓ Ph.D. Graduation score (18.65 out of 20)
- ✓ Ph.D. Thesis score (19.75 out of 20)
- ✓ Ph.D. Thesis title: Evaluation of the effect of VSIG-3(IGSF11) gene silencing on the growth and progression of melanoma cell line and T cell activity

Teaching experience:

1. Teaching Fellow, Tabriz University of Medical Sciences, “Practical Immunology” to Pharmacy, Nursing, and Surgical Technologist Students (2015-2017)
2. Teaching Fellow, Shahid Beheshti University of Medical Sciences, “Practical Immunology” to Medical, Pharmacy, and Dental Students (2020-2022)

Publications:

- 1- [Shekari N](#), Baradaran B, Shanehbandi D, Kazemi T. Circulating MicroRNAs: Valuable Biomarkers for the Diagnosis and Prognosis of Gastric Cancer. *Curr Med Chem*. 2018 Feb 21;25(6):698-714. doi: 10.2174/0929867324666171003123425. PMID: 28971758.
- 2- Zarredar H, Ansarin K, Baradaran B, [Shekari N](#), Eyvazi S, Safari F, Farajnia S. Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications. *Anticancer Agents Med Chem*. 2018;18(14):1991-2005. doi: 10.2174/1871520618666180808125459. PMID: 30088452.
- 3- [Shekari N](#), Asghari F, Haghnavaaz N, Shanehbandi D, Khaze V, Baradaran B, Kazemi T. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer. *Anticancer Agents Med Chem*. 2019;19(3):304-309. doi: 10.2174/1871520619666181213110258. PMID: 30543177.
- 4- Hemmatzadeh M, Babaie F, Ezzatifar F, Mohammadi FS, Ebrazeh M, Golabi Aghdam S, Hajaliloo M, Azizi G, Gowhari Shabgah A, [Shekari N](#), Sehati N, Hosseinzadeh R, Mohammadi H, Babaloo Z. Susceptibility to ERAP1 gene single nucleotide polymorphism modulates the inflammatory cytokine setting in ankylosing spondylitis. *Int J Rheum Dis*. 2019 Apr;22(4):715-724. doi: 10.1111/1756-185X.13494. Epub 2019 Feb 10. PMID: 30740926.
- 5- Javadian M, Gharibi T, [Shekari N](#), Abdollahpour-Alitappeh M, Mohammadi A, Hossieni A, Mohammadi H, Kazemi T. The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasis. *J Cell Physiol*. 2019 May;234(5):5399-5412. doi: 10.1002/jcp.27445. Epub 2018 Nov 22. PMID: 30565667.
- 6- Haghnavaaz N, Asghari F, [Shekari N](#), Shanehbandi D, Javadian M, Mohammadi A, Baradaran B, Kazemi T. Paclitaxel May Inhibit Epithelial-Mesenchymal Transition Properties of Triple-negative Breast Cancer Cell Line via Altering the Expression of EMT-promoting and-inhibiting MicroRNAs. *Middle East Journal of Cancer*. 2020 Jan 1;11(1):42-9.
- 7- Alizadeh Z, Mahami-Oskouei M, Spotin A, Kazemi T, Ahmadpour E, Cai P, Shanehbandi D, [Shekari N](#). Parasite-derived microRNAs in plasma as novel promising biomarkers for the early detection of hydatid cyst infection and post-surgery follow-up. *Acta Trop*. 2020 Feb;202:105255. doi: 10.1016/j.actatropica.2019.105255. Epub 2019 Nov 1. PMID: 31682814.
- 8- [Shekari N](#), Javadian M, Ghasemi M, Baradaran B, Darabi M, Kazemi T. Synergistic Beneficial Effect of Docosahexaenoic Acid (DHA) and Docetaxel on the Expression Level of Matrix Metalloproteinase-2 (MMP-2) and MicroRNA-106b in Gastric Cancer. *J Gastrointest Cancer*. 2020 Mar;51(1):70-75. doi: 10.1007/s12029-019-00205-0. PMID: 30680612.
- 9- Javadian M, [Shekari N](#), Soltani-Zangbar MS, Mohammadi A, Mansoori B, Maralbashi S, Shanehbandi D, Baradaran B, Darabi M, Kazemi T. Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic

conditions. *J Cell Biochem.* 2020 Mar;121(3):2416-2427. doi: 10.1002/jcb.29464. Epub 2019 Nov 12. PMID: 31713924.

10- [Shekari N](#), Javadian M, Ghaffari S, Baradaran B, Darabi M, Kazemi T. DHA Abolishes the Detrimental Effect of Docetaxel on Downregulation of the MICA via Decreasing the Expression Level of MicroRNA-20a in Gastric Cancer. *J Gastrointest Cancer.* 2020 Jun;51(2):545-551. doi: 10.1007/s12029-019-00280-3. PMID: 31368060.

11- [Shekari N](#), Kazemi T, Moradi M, Eghbali E, Sepehri B, Khaze Shahgoli V, Shirmohamadi M. Study of the Effect of Linoleic Acid on the Expression Level of MicroRNA-106b and MicroRNA-20a and their Related Target MHC Class I Chain-related Protein A in Docetaxel-treated Gastric Cancer Cells. *Middle East Journal of Cancer.* 2021 Jul 1;12(3):342-9.

12- Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, [Shekari N](#), Namvar L, Zarredar H. Combination Therapy with KRAS and P38 α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line. *J Gastrointest Cancer.* 2022 Sep;53(3):597-604. doi: 10.1007/s12029-021-00667-1. Epub 2021 Jul 22. PMID: 34292499.

13- Tabnak P, Mafakheri A, Haji Emsailpoor Z, Kazemi T, [Shekari N](#). Regulatory interplay between microRNAs and WNT pathway in glioma. *Biomed Pharmacother.* 2021 Nov;143:112187. doi: 10.1016/j.biopha.2021.112187. Epub 2021 Sep 21. PMID: 34560532.

14- Elieh Ali Komi D, [Shekari N](#), Soofian-Kordkandi P, Javadian M, Shanehbandi D, Baradaran B, Kazemi T. Docosahexaenoic acid (DHA) and linoleic acid (LA) modulate the expression of breast cancer involved miRNAs in MDA-MB-231 cell line. *Clin Nutr ESPEN.* 2021 Dec;46:477-483. doi: 10.1016/j.clnesp.2021.09.006. Epub 2021 Sep 20. PMID: 34857238.

15- [Shekari N](#), Asadi M, Akbari M, Baradaran B, Zarredar H, Mohaddes-Gharamaleki F, Anvarnia A, Baghbanzadeh A, Shanehbandi D. Autophagy-regulating microRNAs: two-sided coin in the therapies of breast cancer. *Eur Rev Med Pharmacol Sci.* 2022 Feb;26(4):1268-1282. doi: 10.26355/eurrev_202202_28120. PMID: 35253184.

16- Shadbad MA, Ghorbaninezhad F, Hassanian H, Ahangar NK, Hosseinkhani N, Derakhshani A, [Shekari N](#), Brunetti O, Silvestris N, Baradaran B. A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study. *Front Med (Lausanne).* 2022 Oct 31;9:1027758. doi: 10.3389/fmed.2022.1027758. PMID: 36388933; PMCID: PMC9659572.

17- Shanehbandi D, Asadi M, Seyedrezazadeh E, Zafari V, [Shekari N](#), Akbari M, Rahbarnia L, Zarredar H. MicroRNA-Based Biomarkers in Lung Cancer: Recent Advances and Potential Applications. *Curr Mol Med.* 2023 May 30;23(7):648-667. doi: 10.2174/2772432817666220520085719. PMID: 35619321.

18- [Shekari N](#), Shanehbandi D, Kazemi T, Zarredar H, Baradaran B, Jalali SA. VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy. *Cancer Cell Int.* 2023 Nov 7;23(1):265. doi: 10.1186/s12935-023-03116-0. PMID: 37936192; PMCID: PMC10631023.

- 19-** Firoozi MR, Sadeghi-Mohammadi S, Asadi M, [Shekari N](#), Seyed Nejad F, Alizade-Harakiyan M, Soleimani Z, Zarredar H. Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study. *Cell Biochem Funct.* 2024 Jan;42(1):e3919. doi: 10.1002/cbf.3919. PMID: 38269512.
- 20-** [Shekari N](#), Abbasi-Kenarsari H, Baradaran B, Kazemi T. Docosahexaenoic Acid (DHA) Impairs Docetaxel-Induced Up-regulation of miR-30a-5p and miR-126-5p Tumor Suppressors in Gastric Cancer Cell Line. *Iranian Journal of Blood and Cancer* 2024; 16 (1) :89-96 URL: <http://ijbc.ir/article-1-1509-en.html>
- 21-** Elieh-Ali-Komi D, Kazemi T, [Shekari N](#), Farzamifar P, Eghbali E, Mansoori B, Baradaran B, Shirmohamadi M. Linoleic Acid Modulates the Expression of Metastatic and Angiogenic Markers MMP-2 and Talin-2 in Gastric Cancer Cell Line MKN-45. *Iran J Public Health.* 2024 Jul;53(7):1612-1620. doi: 10.18502/ijph.v53i7.16055. PMID: 39086406; PMCID: PMC11287596.
- 22-** Maralbashi S, Salari F, Aslan C, [Shekari N](#), Javadian M, Asadi M, Kazemi T. Comparative Study of the Effects of Docosahexaenoic Acid, Linoleic Acid, and Taxol in Decreasing the Expression of miR-10b, and miR-20a OncomiRs, and their Target Major Histocompatibility Complex Class I Chain-Related Proteins A (MICA) in Triple-Negative Metastatic Breast Cancer Cell Line. *ImmunoAnalysis.* 2024;4(1):7-. doi: 10.34172/ia.4080.
- 23-** Aslan C, Maralbashi S, [Shekari N](#), Javadian M, Shomali N, Kazemi T. Differential effects of docosahexaenoic acid (DHA) and linoleic acid (LA) on miR-101 and miR-342 tumor suppressor microRNAs in Taxol-treated HER2-positive breast cancer cells. *Clin Nutr ESPEN.* 2024 Oct;63:502-507. doi: 10.1016/j.clnesp.2024.07.007. Epub 2024 Jul 22. PMID: 39047867.
- 24-** [Shekari N](#), Shanehbandi D, Baghbani E, et al. VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study. *Naunyn Schmiedebergs Arch Pharmacol.* Published online October 4, 2024. doi:10.1007/s00210-024-03491-z.
- 25-** Parhizkar F, [Shekari N](#), HajiEsmailPoor Z, et al. Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms. *Hum Immunol.* 2025;86(3):111298. doi:10.1016/j.humimm.2025.111298

Presentation in Congress:

1- [Shekari N](#), Asghari F, Haghnavaaz N, Shanehbandi D, Khaze V, Baradaran B, Kazemi T; Docetaxel differentially alters the expression level of mir-21 and Let-7a in gastric cancer cell lines (Poster presentation); International congress Cancer prevention & early detection Integration of research & action-28_30 January 2017- Tehran, Iran.

2- [Najibeh Shekari](#), Mahsa Javadian, Sima Ghaffari, Maedeh Moradi, Masoud Shirmohammadi, Tohid Kazemi; Synergistic effect of oshahexaenoic acid (DHA) with etaxel in decreasing the expression level of miR-20a, a MICA-regulating oncomiR, in metastatic gastric cancer cell line(Poster presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

3- [Najibeh Shekari](#), Mahsa Javadian, Motahhreh Ghasemi, Parviz Farzamifar, Masoud Shirmohammadi, Tohid Kazemi; Investigating the effects of Docosahexaenoic acid (DHA), Linoleic Acid (LA) alone or in combination with etaxel on the expression of MMP-2 and Talin-2, and their regulating microRNAs in metastatic gastric cancer cell line (Poster presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

4- Cynthia Aslan, Mahsa Javadian, [Najibeh Shekari](#), Sepideh Maralbashi, Navid Shomali, Tohid Kazemi; Synergistic effect of Docosahexaenoic acid (DHA) and Linoleic acid (LA) with Taxol in up-regulating the expression of miR-101, but not miR-342 tumor suppressor microRNAs, in HER2-positive breast cancer cell line (Poster presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

5- Navideh Haghnavaaz, Faezeh Asghari, [Najibeh Shekari](#), Behzad Baradaran, Tohid Kazemi; MiR-199a-5p may sensitize the triple-negative breast cancers to paclitaxel chemotherapy (Poster presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

6- Sepideh Maralbashi, Farhad Salari, Mahsa Javadian, [Najibeh Shekari](#), Cynthia Aslan, Milad Asadi, Tohid Kazemi; Comparative study of the effects of Docosahexaenoic acid (DHA), Linoleic acid (LA) and Taxol in decreasing the expression of miR-10b and miR-20a oncomirs in triple-negative metastatic breast cancer cell line (Poster presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

7- M. Javadian, [N. Shekari](#), M. Soltani, A. Mohammadi, B. Baradaran, D. Shanehbandi, T. Kazemi; Comparative study of the combinatory effects of Docosahexaenoic acid (DHA) and Linoleic acid (LA) with Taxol on the expression of metastasis related genes and microRNAs in triple-negative metastatic breast cancer cell line (Oral presentation); 14th International Congress of Immunology & Allergy. 26-28 April 2018. Tehran-Iran.

8- Najibeh Shekari, Dariush Shanehbandi, Seyed Amir Jalali, Behzad Baradaran; Silencing V-set and immunoglobulin domain containing 3 (VSIG-3) reduced cell viability in the A2058 melanoma cell line (Mini-Oral presentation); 16th International Congress of Immunology & Allergy. 27-29 April 2023. Tehran-Iran.

9- Najibeh Shekari, Dariush Shanehbandi, Behzad Baradaran, Seyed Amir Jalali; Silencing of VSIG-3 simultaneously suppresses A2058 melanoma cell progression and induces anti-tumoral cytokine profile in human T cells (Oral presentation); The 15th International congress of Medical Lab. and Clinic. 25-28 January 2023. Tehran-Iran.

10- Najibeh Shekari, Dariush Shanehbandi, Tohid Kazemi, Habib Zarredar, Seyed Amir Jalali, Behzad Baradaran; VISTA and Its Ligands: The Next Generation of Promising Therapeutic Targets in Immunotherapy (Poster presentation); The 15th International congress of Medical Lab. and Clinic. 25-28 January 2023. Tehran-Iran.

Peer-Reviewing Experience:

❖ Scientific Journals:

1. Cancer Cell International (ISSN: 1475-2867, Impact Factor: 5.8): 7
2. Technology in Cancer Research & Treatment (ISSN: 15330346, Impact Factor: 2.8): 5
3. Scientific Reports (ISSN: 2045-2322, Impact Factor: 4.6): 3
4. Bioengineered (ISSN: 2165-5979, Impact Factor: 4.9): 2
5. BMC Cancer (ISSN: 1471-2407, Impact Factor: 3.8): 2
6. BMC Medical Genomics (ISSN: 1755-8794, Impact Factor: 2.7): 2
7. BMC Gastroenterology (ISSN: 1471-230X, Impact Factor: 2.4): 1
8. Biochemical Genetics (ISSN: 0006-2928, Impact Factor: 2.4): 1
9. Immunogenetics (ISSN: 0093-7711, Impact Factor: 3.2): 1
10. Molecular Cancer (ISSN: 1476-4598, Impact Factor: 37.3): 1
11. Naunyn-Schmiedeberg's Archives of Pharmacology (ISSN:0028-1298, Impact Factor:3.6):1
12. Biology Direct (ISSN: 1745-6150, Impact Factor: 5.7):1

❖ Congress:

1. Referee Committee member, 15th International congress of Medical Lab. and Clinic, January 2024, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Referee Committee member, 16th International congress of Medical Lab. and Clinic, December 2024, Tehran University of Medical Sciences, Tehran, Iran

Book:

One of the translators of Janeway's Immunobiology, 9th Edition, 2017, Haidari Publication, Tehran. Iran

Awards:

1. Best Mini-Oral presentation in 16th International Congress of Immunology & Allergy, 2023.
2. Outstanding National Researcher Student of the Year 2024.
3. Achieved a top ranking in the 2nd National Problem-Solving Competition organized by the National Elite Foundation (Shahid Babaei Program) in 2024.

Workshops and Training Courses:

1. GraphPad Prism Software – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
2. Reference Management Software – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
3. Selecting High-Impact Journals for Article Publication – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
4. Introduction to CRISPR/Cas9 – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
5. Gene Editing System: Concepts and Approaches – Alzahra University, Tehran
6. Graphing and Data Analysis in Biological Research – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
7. Basics and Principles in Primer Design: Theory and Practical – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
8. Design and Analysis of qRT-PCR Results: Theory and Practical – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
9. Introduction to Python Programming – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences
10. Isolation of Mesenchymal Stem Cells from Adipose Tissue – Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences.

Membership:

1. Member of the Office for Exceptional Talents at Shahid Beheshti University of Medical Sciences (Ph.D.).
2. Active member of the Iranian Society for Immunology and Allergy.
3. Member of the Research and Technology Committee of the Iranian Society for Immunology and Allergy (2021-now).

Professional Experiences:

1. **Standard molecular biology techniques:** DNA and RNA Extraction, PCR, qRT-PCR, Electrophoresis, Gene silencing with siRNA, and microRNA assays
2. **Immunology and biology techniques:** Cell Culture, MTT Assay, Wound healing assay, Cell Cycle assay, PBMC isolation, T-cell investigations, ELISA, and Western blot
3. **Software Skills:** Official Microsoft, Graph-pad Prism, SPSS, EndNote, Biorender, FlowJo, ImageJ, and online bioinformatics databases